How Your Body Sabotages Cancer Treatments

Scientist examining samples under a microscope in a laboratory

Your immune system may be quietly sabotaging your cancer treatment — and scientists just found the switch that turns that sabotage off.

Quick Take

A protein called SLAMF6 acts like a built-in brake on your immune cells, slowing down their ability to fight cancer.
New research shows that blocking SLAMF6 with an antibody can wake up exhausted immune cells and shrink tumors in lab models.
The findings apply to multiple cancers, including melanoma and a blood cancer called acute myeloid leukemia.
The science is promising but still early — no large human trials have confirmed these results yet.

Why Immunotherapy Sometimes Stops Working

Cancer immunotherapy has changed medicine. Drugs called checkpoint inhibitors — like those targeting the PD-1 protein — teach your immune system to attack tumors. But for many patients, the treatment works for a while, then stops. Tumors come back. Doctors have long suspected something inside the immune cells themselves was to blame. Now, a 2026 study published in Nature may have found a key culprit. ^[3]

The protein in question is called SLAMF6. It sits on the surface of T cells, which are the immune system’s main cancer-fighting soldiers. Researchers found that SLAMF6 triggers itself by binding to copies of itself on the same cell — a process called a “cis interaction.” That self-binding sends a signal that weakens the T cell. It reduces the cell’s ability to attack, and it cuts the production of strong, long-lasting T cells. ^[3] One science news outlet described it plainly as an “internal brake” that works independently of the tumor itself. ^[1]

The Cells That Burn Out First

Not all T cells are affected equally. SLAMF6 is found in high amounts on a specific group called progenitor exhausted T cells — sometimes called stem-like exhausted T cells. ^[3] These are important because they are the source of fresh cancer fighters. If they burn out or stay suppressed, the immune response fades. An earlier study in the journal eLife confirmed that mice without SLAMF6 had T cells with stronger killing ability and achieved longer-lasting tumor remission in melanoma. ^[2] That study called SLAMF6 “a constitutive inhibitory immune receptor” — meaning it suppresses immune activity by default, not just in certain conditions. ^[2]

Researchers at MD Anderson Cancer Center found similar results. Blocking SLAMF6 corrected T cell dysfunction and reduced tumor growth in their models. ^[4] A separate Nature Communications study focused on acute myeloid leukemia — a fast-moving blood cancer — and found that removing SLAMF6 from leukemia cells made those cells vulnerable to T cell attack. A fully human antibody designed to block SLAMF6 killed leukemia cells effectively in both lab and humanized animal models. ^[5]

How the Antibody Works

The new antibodies work by breaking up the cis interaction — that self-binding process that puts T cells to sleep. When researchers blocked SLAMF6 this way, T cell activation increased sharply, the share of exhausted T cells dropped, and tumor growth slowed in animal models. ^[3] The researchers described their antibodies as leading candidates that outperform existing tools for studying and targeting this pathway. ^[1] That is a bold claim, and it is worth noting it comes from the research team itself, not from an independent head-to-head clinical trial.

That distinction matters. The evidence so far is strong in the lab. Mouse models, cell culture experiments, and humanized animal systems all point in the same direction. But the Nature abstract itself admits that SLAMF6’s role “remains ambiguous” because it has both activating and inhibitory effects depending on context. ^[3] The leukemia study also found no clear link between SLAMF6 levels and patient survival in real patient data. ^[5] These are not reasons to dismiss the research — they are reasons to wait for human trial results before drawing firm conclusions.

Promising, But the Hard Part Comes Next

The history of cancer immunotherapy is full of targets that looked perfect in mice and stumbled in humans. SLAMF6 may be different. The biology is well-reasoned, the results across multiple cancer types are consistent, and the antibody design is sophisticated. But no completed randomized human trial has yet tested whether blocking SLAMF6 extends survival, prevents relapse, or improves quality of life in real patients. ^[2]^[3]^[5] Safety data — including whether blocking this protein could trigger dangerous immune reactions — has not been published in the available record.

The next steps are clear. Researchers need phase 1 and phase 2 human trials that measure not just immune cell behavior, but actual patient outcomes like progression-free survival. They need independent labs to replicate the findings across more cancer types. And they need head-to-head comparisons with existing checkpoint drugs to know whether SLAMF6 blockade adds real value. The science behind this brake is compelling. Whether releasing it saves lives is the question that only human trials can answer.